University of North Carolina at Chapel Hill, Chapel Hill, NC
Brigham Young University at Provo, Provo, UT
Bradley Layton, PhD, FISPE, is a Director of Epidemiology at RTI Health Solutions with vast experience leading studies using existing health care data sets to evaluate the use, safety, and effectiveness of pharmaceuticals, vaccines, and other medical products. He has considerable leadership experience in the design, conduct, analysis, and reporting of epidemiologic studies and has over 10 years of experience in the field of pharmacoepidemiology. His experience and publications span a wide range of substantive areas, including renal, cardiovascular, men’s health, vaccines, and pregnancy, and incorporate multidatabase and multinational studies. He has been a project leader or scientific contributor within international consortia of researchers, including the FDA BEST Initiative and Vac4EU. Dr. Layton also has experience with epidemiologic methods, lecturing to clinical and public health audiences about observational study design, large database utilization, and propensity score analysis.
Dr. Layton received his master's and doctorate degrees in epidemiology from the Department of Epidemiology in the Gillings School of Global Public Health, University of North Carolina at Chapel Hill, focusing in pharmacoepidemiology with an emphasis in renal disease. Prior to joining RTI-HS, he was a member of the faculty in the Pharmacoepidemiology Program in the University of North Carolina Department of Epidemiology, and he is currently an adjunct associate professor at the University of North Carolina. Dr. Layton is a fellow and an active member of the International Society of Pharmacoepidemiology, having served on the Scientific Program Committee as the chair of the spotlight poster sessions, on the Public Policy Committee, and as the Chair of the Vaccine Special Interest Group.